- ROUNDTABLE: Pharmacy’s future in sync with technology
- USPLabs agrees to recall and destroy dietary supplement following FDA actions
- Reports: ESI may start 'price war' over new hepatitis C drugs
- Impax Labs, Tolmar receive FDA approval for generic version of Solaraze
- Walmart, other industry groups raise concerns on proposed generic labeling rule
CAMBRIDGE, Mass. — The Food and Drug Administration on Monday approved Aegerion Pharmaceuticals' cholesterol drug, Juxtapid.
The drug — an alternative treatment for patients who have a genetic predisposition to high cholesterol — will carry a boxed warning, the strongest level of FDA warning. Juxtapid will be available only through a restricted program due to risk of liver damage.
Aegerion also will conduct a post-approval study to test the long-term safety and efficacy of Juxtapid, the company said. It plans to launch the drug in January.